A股異動丨康希諾(688185.SH)創歷史新高 一針疫苗已在國內多地開打
格隆匯5月21日丨康希諾(688185.SH)漲近5%,報593.96元創其上市以來新高;康希諾生物-B(6185.HK)亦漲2.76%。消息稱,只打一針的新冠疫苗目前已在北京、上海、天津、浙江、河南、安徽等多地開打。為滿足市場需求,一針疫苗的生產廠商康希諾生物日前正在增加產能。國家衞健委新聞發言人米鋒20日在國務院聯防聯控機制發佈會上介紹,近期,各地羣眾踴躍接種新冠病毒疫苗。截至5月19日,全國累計報吿接種44951.1萬劑次,其中最近8天共接種超過1億劑次。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.